OPENING COMMENTS (9:00 - 9:15)

James Orbinski, Canada, Chairman of Médecins Sans Frontières International

Panel I : THE NATURE OF ACCESS PROBLEMS FOR ESSENTIAL DRUGS AND MEDICAL TECHNOLOGIES (9:15 - 10:45)

Chaired by Eva Ombaka, Pharmaceutical Advisor, Churches Action International

• Bernard Pecoul, France, Médecins Sans Frontières International
• Richard Laing, USA, Associate Professor, Department of International Health, Boston University
• Jerome Dumoulin, France, Universite Pierre Mendes France, Grenoble The consequences of patents on prices, an international review..
• Eric Sawyer, USA, ACT-up New York
• Saree Aongsomwang, Thailand, Thai Consumer Foundation

Panel II : INTERNATIONAL LAW AND COMPULSORY LICENSING (11:00 - 12:30)

Chaired by Dr. Zafar Mirza, Pakustan, Coordinator, The Network, Association for Rational Use of Medication.

• Dr Adrian Otten, WTO, Director Intellectual Property Division What is compulsory licensing and what is the role of WTO in compulsory licensing?
• Prof Bernard Remiche, Belgium, Departement de droit economique et social, Universite de Louvain
• Dr. Carlos M. Correa, Argentina, Centro de Estudos Avanzados, Universidad de Buenos Aires

LUNCH (12:30 - 1:30)

Panel III : PRACTICAL ISSUES RELATING TO COMPULSORY LICENSING (1:45 - 3:15)

Chaired by Ellen't Hoen, the Netherlands, MSF, HAI

• Carlotta Graffigna, Director Advisory, WIPO, WIPO's assistance in drafting legislation on compulsory licensing.
• James Love, USA, Consumer Project on Technology Methods of determining a reasonable compensation in compulsory licensing.
• Jon F. Mertz,Center for Bioethics, University of Pennsylvania, Compulsory licensing in new medical technologies.
• Bill Hadad, USA, CEO MIR Pharmaceuticals Compulsory licensing in practice: the generic industry experience.

Panel IV : VIEWS AND PERSPECTIVES ON COMPULSORY LICENSING (3:30 - 5:15)

Chaired by Dr. Krisantha Weerasuriya, Sri Lanka, University of Colombo, Department of Pharmacology.

• Dr. Michael Scholtz, WHO, Executive Director, Health Technology and Drug Cluster.
• David Waters, USA, IFPMA, SmithKline Beecham The position of the IFPMA on compulsory licensing.
• Jim Keon, Canada, Co-Director IGPA, President CDMA The position of the generic insutry on compulsory licensing.
• Nadine Gasman, Mexico, AIS/HAI The public health implications of not granting licenses.
• Paul Toh, Thailand, GNP+/APN+/APCASO The Thai movement on compulsory licensing of pharmaceutical patents.
• Desmond Johns, South Africa, Permanent Mission in Geneva The South African experience in access to drugs and compulsory licensing.
• Invited, Lois Boland, USA, Patent and Trademarks Office The US position on compulsory licensing on the national and international levels.
• DR. K. Balasubramaniam, Malaysia, Pharmaceutical Advisor, CIROAP The consumer perspective on compulsory licensing.

Bernard Pecoul, France, Médecins Sans Frontières International

rev 1.0